Latest news with #CROSSJECT
Yahoo
a day ago
- Business
- Yahoo
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
Press release Launch of a capital increase with preferential subscription rights for nearly 5 million euros Issuance of new shares for an initial total amount of around €5.0 million, with shareholders maintaining their preferential subscription rights (DPS), which may be increased to around €5.7 million if the extension clause is exercised (the 'Offer'). Intentions and commitment to subscribe by existing shareholders and Vatel Capital, as a new institutional investor, for a total amount of approximately 3.7M€, already representing 76,4% of the transaction. Subscription price for the new shares set at €1.40, representing a 22.6% discount to the closing price of the CROSSJECT share on June 3, 2025 (€1.808) and a 21.3% discount to the theoretical value of the CROSSJECT share ex-rights. Subscription period from June 12, 2025 to June 20, 2025 included. Dijon, France 4 June 2025 (8.10 PM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration of ZEPIZURE®, launches a capital increase with preferential subscription rights ('DPS'), for an initial total amount of 4,978,678.60 euros ('the Offer'), which may be increased to 5,725,479.20 euros if the extension clause is exercised. Objectives of the capital increase As announced on May 7 and May 20, CROSSJECT continues to focus on the preparation of the EUA submission to the FDA, and remains on schedule to finalize production of the validation batches in June. CROSSJECT will transfer these data as the final addition into the ZEPIZURE® EUA submission platform. CROSSJECT expects a first confirmation of receipt from the FDA one month after submission. In addition, CROSSJECT has started a first manufacturing cycle of EUA batches, intended for the first delivery of the CHEMPACK program as part of the US national preparedness against chemical threats, in agreement with its American partner, the Biomedical Advanced Research and Development Authority (BARDA). CROSSJECT also continues to allocate a significant portion of its resources to its infrastructure in the United States and to its other product candidates. As planned, CROSSJECT is pursuing the other stages in the development of ZEPIZURE® for its second NDA filing in the second quarter of 2026, as well as developments relating to ZENEO Adrenaline and ZENEO Hydrocortisone. The Company intends to use the net proceeds of the issue as follows: - Approximately 60% will be allocated to the final development phases of ZEPIZURE® and the start-up of the initial production stages, including the building up of related inventories, prior to any reimbursement by its American partner; - Approximately 40% will be used to finance R&D for its other projects, ZENEO® Adrenaline and ZENEO® Hydrocortisone, to repay certain financial creditors, and to cover general and administrative expenses and corporate development costs, particularly in the United States. In the event of the Offer being limited to 75% of the issue, i.e. around 3.7 million euros, CROSSJECT will allocate the net proceeds to the above activities on a prorata basis, giving priority to activities linked to the registration and production of ZEPIZURE®. With the net proceeds of the issue, the Company estimates that its net working capital would be sufficient to meet its obligations until the end of 2025, assuming the first payments from its American partner following the first deliveries. In order to preserve its financial flexibility and ensure its cash position in 2025 until receipt of these first payments, expected from the third quarter, the Company continues to study dilutive and non-dilutive financing alternatives. The Company could also receive additional funds from the exercise of the warrants issued on December 13, 2024, up to a maximum amount of around €10.2 million, to meet additional financing needs. Future payments from its US partner beyond 2025 will be a major contribution to the Company's financing needs. Terms and conditions of the capital increase Nature and legal framework of the transaction The capital increase involves the issue of new shares with maintenance of the shareholders' preferential subscription rights. The CEO, acting on the basis of the 7th and 13th extraordinary resolutions of the Combined General Meeting of June 27, 2024, in accordance with the authorization granted to him by the Supervisory Board on May 19, 2025, and pursuant to the sub-delegation granted to him by the Executive Board on May 19, 2025, decided on June 4, 2025 to carry out a capital increase through the issue of ordinary shares with preferential subscription rights, the terms of which are detailed in this press release. Share capital – Number of shares issued CROSSJECT's share capital comprises 46,230,596 fully subscribed and paid-up shares with a par value of €0.1 each, listed on the Euronext Growth market of Euronext Paris. Based on the number of shares currently outstanding, 3,556,199 new shares will be issued (which may be increased to 4,089,628 new shares if the extension clause is exercised), on the basis of 1 new share for every 13 existing shares held (13 preferential subscription rights will entitle the holder to subscribe for 1 new share). The initial issue of 3,556,199 new ordinary shares with a par value of €0.1, at a price of €1.40 each, would represent a capital increase of a nominal amount of €355,619.90, together with a share premium of €4,623,058.70, giving gross proceeds of €4,978,678.60. Extension clause In the event of oversubscription and full exercise of the extension clause, the number of ordinary shares that could be issued would be increased to 4,089,628 shares, representing a capital increase of a nominal amount of €408,962.80 and a share premium of €5,316,516.40, i.e. gross proceeds of €5,725,479.20. Subscription price The subscription price per new share is €1.40, and must be fully paid up in cash at the time of subscription. The issue price of €1.40 per share represents a discount of 22.6% to the closing price of the CROSSJECT share on June 3, 2025 (€1.808) and a discount of 21.3% to the theoretical value of the CROSSJECT share ex-rights. The issue price represents a discount of 22,6% and 19,2% compared to the closing price on June 3, 2025, the 30 day weighted average trading price respectively and a premium of 3,3% over the 60 day weighted average trading price. Subscription terms Subscription opening and closing dates from June 12, 2025 to June 20, 2025 inclusive. Subscriptions on an irreducible basis Subscription of the new shares is reserved by preference for existing shareholders, or assignees of their preferential subscription rights, who may subscribe on an irreducible basis, at the rate of 1 new share for 13 preferential subscription rights, without taking fractions into account. Shareholders or assignees of their preferential subscription rights who do not hold a sufficient number of existing shares or preferential subscription rights to obtain a whole number of new shares may buy or sell the number of preferential subscription rights needed to reach the multiple leading to a whole number of new shares. Subscriptions on a reducible basis Shareholders will have the right to subscribe for shares on a reducible basis, in proportion to their rights and up to the number of shares they request. At the same time as they submit their irreducible subscriptions, shareholders or assignees of their rights may subscribe for as many new shares as they wish, in addition to the number of new shares resulting from the exercise of their irreducible rights. Any new shares not taken up by irrevocable subscriptions will be distributed and allocated to reducible subscribers. Subscription orders on a reducible basis will be served up to the limit of their numbers. A notice published by Euronext will make known, where applicable, the allocation scale for subscriptions on a reducible basis. Exercise of preferential subscription rights To exercise their preferential subscription rights, holders must submit a request to their authorized financial intermediary at any time between June 12, 2025 and June 20, 2025 inclusive, and pay in full the amount of their subscription. Each subscription must be accompanied by a payment of the subscription price in cash or by offsetting liquid and due claims on the Company. Subscriptions that have not been paid up in full will be cancelled, without the need for formal notice. Preferential subscription rights not exercised by the close of the subscription period will automatically lapse. Preferential subscription rights must be exercised by their beneficiaries, at risk of being cancelled before the end of the subscription period, i.e. June 20, 2025. Listing of preferential subscription rights The preferential subscription rights will be detached on June 10, 2025 for the benefit of holders of existing shares recorded in their securities account at the end of the accounting day of June 9, 2025, on the basis of one preferential subscription right per existing share of the Company. They will be listed and traded on Euronext Growth under ISIN code FR00140100I2 from June 10, 2025 to June 18, 2025 included. Theoretical value of the preferential subscription right €0.03 based on the closing price of the Company's shares on June 3, 2025, i.e. €1.808. The subscription price of €1.40 per share represents a discount of 21.30% to the theoretical value of the share after detachment of the right. Paying agents - Subscription payments Funds paid in support of cash subscriptions will be centralized by Crédit Industriel et Commercial (CIC Market Solutions - Émetteur Adhérent Euroclear n°025) 6 avenue de Provence 75452 Paris Cedex 9. Preferential subscription rights detached from treasury shares held by the Company In accordance with article L. 225-210 of the French Commercial Code, the Company may not subscribe for its own shares. Preferential subscription rights detached from shares owned by the Company will be sold on the market before the close of the preferential subscription rights trading period. Free subscription requests In addition to the possibility of subscribing on an irreducible and reducible basis in accordance with the terms and conditions set out above, any individual or legal entity, whether or not holding preferential subscription rights, may subscribe to this capital increase on an unrestricted basis. Persons wishing to subscribe on a voluntary basis must send their request to Crédit Industriel et Commercial (CIC Market Solutions - Émetteur Adhérent Euroclear n°025) 6 avenue de Provence 75452 Paris Cedex 9, OR to their authorized financial intermediary at any time during the subscription period and pay the corresponding subscription price. In accordance with the provisions of Article L. 225-134 of the French Commercial Code, unrestricted subscriptions will only be taken into account if the irreducible and reducible subscriptions have not absorbed the entire capital increase, it being specified that the Executive Board will have the option of freely allocating the unsubscribed shares, in whole or in part, among the persons (shareholders or third parties) of its choice who have made unrestricted subscription requests. Indicative timetable for the operation The table below sets out the expected timetable for the transaction as at the date of this press release: June 4, 2025 Decision by the Chairman of the Executive Board to carry out a capital increase with preferential subscription rights, and to set the terms and conditions of the transaction. Press release announcing the transaction June 6, 2025 Publication of the information notice in the BALO June 10th 2025 Detachment of preferential subscription rights and start of trading of preferential subscription rights on Euronext Growth Paris June 12th, 2025 Opening of the subscription period June 18, 2025 End of DPS trading period June 20, 2025 End of subscription period june 24, 2025 Decision to exercise the extension clause Press release announcing the results of the Offer june 25, 2025 Publication by Euronext Paris of the notice of admission of the final amount of the capital increase and the allocation scale for subscriptions subject to reduction (reducible basis) june 27, 2025 Issue and settlement of new shares Admission and start of trading of the new shares on Euronext Growth Paris The above timetable will be followed by the regulatory publications of the new total number of shares and the usual legal formalities. Undertaking by the Company to refrain from trading in the Company's shares and lock-up agreement The Company has entered into a lock-up agreement for a period expiring 90 calendar days following the settlement-delivery date of the new shares, subject to certain customary exceptions. Commitment and subscription intentions The holder of convertible bonds (OCAs) affiliated with Heights Capital Management, Inc ("Heights") has indicated its intention to subscribe to the proposed capital increase by offsetting against its claim of 555,645 euros corresponding to the cash redemption of the final maturity date of the convertible bonds of April 28, 2025, representing 11.1% of the capital increase (excluding the exercise of the Extension Clause). Under the terms of a subscription undertaking signed on June 4, 2025, Vatel Capital ("Vatel Capital"), an investor who was not a shareholder at the date of this press release, has irrevocably undertaken to subscribe to the capital increase on an irreducible and reducible basis for a total amount of 2,000,000 euros, representing 40.1% of the capital increase (excluding the exercise of the Extension Clause). In accordance with its intention announced on May 20, 2025, Gemmes Venture, the Company's reference shareholder, has undertaken to underwrite the Offer up to the amount necessary for its completion (i.e. 75% of the initial issue amount). In order to enable Heights and Vatel Capital to participate in the issue, Gemmes Venture has also undertaken to sell its DPS for a price of 1 euro per block of DPS to Heights and Vatel Capital1 . At the same time, Gemmes Venture will subscribe to the planned capital increase on an irreducible basis for the balance of its preferential subscription rights, i.e. 276,068, and on a reducible basis for an amount equivalent to what it would have obtained by exercising its preferential subscription rights, i.e. a total amount of 1,250,000 euros, representing 25.1% of the capital increase (excluding the exercise of the Extension Clause). In total, the intentions and commitments of these two existing shareholders and of Vatel Capital to subscribe for the shares on an irreducible and reducible basis represent 3,805,645 euros, or 76.4% of the planned capital increase (excluding the extension clause). Guarantee The offer will not be subject to a performance guarantee within the meaning of article L.225-145 of the French Commercial Code. Ownership date and listing of the new shares The new shares, which will be subject to all the provisions of the Articles of Association, will be created with dividend rights. They will be assimilated to existing shares as soon as they are issued. They will be the subject of an application for admission to trading on Euronext Growth. They will be listed on the same line as existing shares and will be fully assimilated to them as soon as they are admitted for trading. Settlement-delivery and admission of the new shares to trading on Euronext Growth Paris is scheduled for June 27, 2025. Undertaking to retain shares None. Impact of the capital increase on shareholders' equity per share The table below summarizes the dilutive impact of the capital increase in euros on shareholders' equity per share under different dilution scenarios linked to the issue: Impact on shareholders' equity in euros per share Non-diluted basis Primary diluted basis(a) Total diluted basis with conversion/amortisation of OCAs(b) Case 1 Case 2 Before issue of new shares -0,05 € 0,16 € 0,27 € 0,25 € After issue of 3,556,199 new shares (100% of the Offer) 0,06 € 0,24 € 0,34 € 0,32 € After issue of 2,667,150 new shares (i.e. 75% of the Offer in the event of limitation) 0,03 € 0,22 € 0,32 € 0,30 € After issue of 4,089,628 new shares (i.e. 115% of the Offer in the event of exercise of the extension clause) 0,07 € 0,25 € 0,35 € 0,33 € (a) Reflects the dilution of : 950,700 shares allocated free of charge by the Company during the vesting period 3,635,556 BSAs issued in December 2024 may give the right to subscribe for a total of 4,544,445, shares at a price of €2.25 per share (four BSAs giving the right to subscribe for five ordinary shares). (b) Reflects the exercise of the bonds convertible into new shares and redeemable for shares (OCAs) issued on February 28, 2024 and February 7, 2025, in accordance with the terms and conditions set out below. The dilution cases relating to the OCAs are based on the assumptions set out below: Case 1 In the event of conversion of all the OCAs at the conversion price of 1.677 euros (subject to adjustment)The Company does not redeem any shares. Case 2 The OCA holder chooses not to convert any OCAs into Company elects to redeem all the OCAs in shares, and the redemption1 euro (subject to the investor holding 9.99% of the Company's capital). Common assumptions Calculations based on the number of shares making up the Company's share capital at the date of this press release, i.e. 46,230,596 shares. The holder of the convertible bonds never holds more than 9.99% of the Company's share capital at each conversion or redemption into shares. Impact of the capital increase on the situation of shareholders who do not subscribe to the transaction For information purposes, the impact of the capital increase on the situation of a shareholder holding 1% of CROSSJECT's share capital prior to the capital increase and not subscribing to it would be as shown below. Shareholding of a shareholder holding 1% of the capital prior to the offer Non-diluted basis Primary diluted basis(a) Total diluted basis with conversion/amortisation of OCAs(b) Case 1 Case 2 Before issue of new shares 1,00 % 0,89% 0,82% 0,78% After issue of 3,556,199 new shares (100% of the Offer) 0.93% 0.84% 0,77% 0,73% After issue of 2,667,150 new shares (i.e. 75% of the Offer in the event of limitation) 0,95% 0,85% 0,78% 0,74% After issue of 4,089,628 new shares (i.e. 115% of the Offer in the event of exercise of the extension clause) 0,92% 0,83 0,77% 0,73% (a) Reflects the dilution of : 950,700 shares allocated free of charge by the Company during the vesting period 3,635,556 BSAs issued in December 2024 may give the right to subscribe for a total of 4,544,445 shares at a price of 2.25 euros per share (four BSAs giving the right to subscribe for five ordinary shares). (b) Reflects the cases of exercise of the Bonds Convertible into New and Redeemable Shares (OCAs) issued on February 28, 2024 and February 7, 2025, in accordance with the terms specified above. CROSSJECT is being advised in this transaction by D'Hoir Beaufre Associé Market Solutions is acting as Lead Manager and Bookrunner. Risk factors relating to the Offer Shareholders who do not exercise their preferential subscription rights will see their stake in the Company's capital diluted; The market for preferential subscription rights may offer only limited liquidity and be subject to high volatility; The market price of the Company's shares could fluctuate and fall below the subscription price of the new shares from the announcement of the offer, during the subscription period or at any time after the close of the offer; The volatility and liquidity of the Company's shares could fluctuate significantly; In the event of a fall in the market price of the Company's shares, preferential subscription rights could lose their value. Shareholders could see their interest in the Company's share capital diluted in the event of a new public offering. Issuer risk factors The Company draws the public's attention to the risk factors relating to its activities presented in section 8. Analysis of business trends in relation to the volume and complexity of business in its 2024 annual report, online on the Company's website ( and in notes 3. a) "Going concern" and 27 "Events after the period-end" to the 2024 annual financial statements. Warning Insofar as the amount of the Offer is less than €8 million (calculated over a 12-month period), the planned issue will not give rise to a prospectus approved by the AMF. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development mainly include solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. *** For further information, please contact: Investor Relationsinvestors@ 1 Gemmes Venture will sell 3,741,536 preferential subscription rights to Heights for a price of 1 euro, to enable it to subscribe to the planned capital increase on an irreducible basis, by offsetting its entire claim (taking into account the preferential subscription rights already held by Heights).Gemmes Venture will also sell 7,301,880 preferential subscription rights at a price of 1 euro to Vatel Capital to enable it to subscribe 561,683 new shares to the planned capital increase. Vatel Capital also reserves the right to acquire other preferential subscription rights on the market and will subscribe to the balance of its subscription commitment on a reducible basis. Attachment Launch of a capital increaseSign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE® in adults, is informing about the recent initiation of coverage by Maxim Group, the US brokerage firm dedicated to biopharmaceutical companies and other emerging growth and technology companies. In a first equity research report titled 'A Robust Needle-Free Auto-Injector Platform for Emergency Therapies', Maxim Group's Equity Research issued a first BUY recommendation on the CROSSJECT share. The price of the CROSSJECT share on the 29th of May 2025, the date of issue of the research report, was €1.77. « We are excited by this first endorsement by a leading broker-dealer firm in the U.S. specialized in emerging growth companies in life sciences. We look forward to fueling the North American investor community with further positive developments in relation with the registration of ZEPIZURE® with the FDA and with the rest of our pipeline », said Patrick ALEXANDRE, CEO of CROSSJECT. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. About Maxim Group Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan. Maxim Group was formed in 2002 as an independent and 100% employee-owned firm providing customized solutions to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of FINRA, SIPC, and NASDAQ. *** For further information, please contact: Investor Relationsinvestors@ Attachment Maxim Group initiates the coverage of theError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment
Press release CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory 's versatility and capacity in anticipation of full product pipeline deployment CROSSJECT developed the ZENEO® Nest, a new module to improve batch aseptic filling of the proprietary glass drug container of the ZENEO® device, to be implemented by December 2025. Consistent with its ability to diversify its financing sources, CROSSJECT obtained a new equipment financing dedicated to the implementation of the ZENEO® Nest. Dijon, France 27 May 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE®, an emergency injectable for the management of epilepsy crises, scales-up key steps in the ZENEO® Factory manufacturing process. The implementation of this innovation, planned for 2025, is a strategic step in anticipation of the broad deployment of ZEPIZURE® and of its other pipeline product candidates. CROSSJECT developed the ZENEO® Nest, a new module to facilitate an automated, high volume aseptic filling of the proprietary glass drug container inside the ZENEO® device. The ZENEO® Nest pre-assembles such containers for faster, batched filling, translating into higher volumes per day within the reserved room units of CROSSJECT's CDMO partners. More importantly, the ZENEO® Nest was designed to be compatible with many filling set-ups or equipment lines in the CDMO industry. As a result, CROSSJECT is able to establish fully ready-to-use filling units within injectables CDMO partners in France or in any geography as the demand for its products grows. The first ZENEO® Nest was successfully experimented with EUROFINS, who will be the initial user. CROSSJECT anticipates a rapid, full implementation by December 2025 of the ZENEO® Nest in its facility in Dijon followed by qualification and final validation steps by Q1 2026. « We are excited by this innovation in our manufacturing process, one of the roots of CROSSJECT's excellence. The ZENEO® Nest makes the triple contribution to increase our control over the productivity and quality of our filling process, to enhance our agility in establishing CDMO relationships for large scale volumes internationally, and to reduce our cost of goods. », said Patrick ALEXANDRE, CEO of CROSSJECT. The deployment of the ZENEO® Nest is in part financed by an equipment loan with LCL, a new banking partner of CROSSJECT, loyal to its strategy to diversify financing sources. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. *** For further information, please contact: Investor Relationsinvestors@ Attachment CROSSJECT implements new manufacturing
Yahoo
20-05-2025
- Business
- Yahoo
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
Press Release CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval The amount of the proposed transaction ('the Offer') might be increased to around 5.8 million euros if the extension clause is exercised; Gemmes Venture, the Company's reference shareholder, announced its intention to guarantee the capital increase in cash up to the amount required for its completion (i.e. 75% of the initial amount of the issue); Heights Capital Management is supporting the Offer. Dijon, France, May 20, 2025 (7.30 AM CET)- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE®, an emergency injectable for the management of epilepsy crises, plans to launch a capital increase with maintenance of preferential subscription rights in early June, for a gross amount of around 5.0 million euros ('the Offer'), which might be increased to around 5.8 million euros if the extension clause is exercised. Patrick ALEXANDRE, CEO of CROSSJECT highlighted: «In line with our progress towards a rapid filing of the ZEPIZURE® dossier with the FDA under the EUA procedure, we aim to have the necessary resources and financial flexibility to meet the demands of our US partner. Subject to FDA approval, our entire team is focused on our ability to deliver in response to the CHEMPACK program in support of US national preparedness against chemical threats. We also continue to be proactive in building our commercial infrastructure in the USA. » Preliminary characteristics of the Offer The planned Offer would consist of a capital increase through the issue of new shares with maintenance of preferential subscription rights. The capital increase would be decided in accordance with the authorization granted by the Supervisory Board at its meeting of May 19, 2025, and with the 7th resolution adopted by the Annual General Meeting of June 27, 2024, under which the shareholders delegated authority to the Managing Board to issue ordinary shares with pre-emptive subscription rights, up to a maximum nominal amount of 900,000 euros, excluding any preservation of rights. The transaction will be the subject of a specific press release at the time of the decision to launch the transaction, setting out the terms and conditions and the timetable. In view of the transaction, CROSSJECT will shortly suspend the exercise of dilutive instruments (warrants1 and convertible bonds ('OCA')2). Objectives of the Offer As announced on May 7, CROSSJECT continues to focus on the preparation of the EUA submission to the FDA and remains on schedule to finalize production of the validation batches in June. In addition, CROSSJECT has started a first production run of EUA batches, intended for the first delivery of the CHEMPACK program as part of the US national preparedness against chemical threats, in agreement with its American partner, the Biomedical Advanced Research and Development Authority (BARDA). CROSSJECT continues to allocate a significant portion of its resources also to its infrastructure in the United States and to its other product candidates. In this context, the Company intends to use the net proceeds of the issue as follows:- Approximately 60% will be allocated to the final development phases of ZEPIZURE® and to the initiation of production steps, including the related build-up of inventories, ahead of any reimbursement by the U.S. partner;- Approximately 40% will be used to finance R&D for its other projects, ZENEO® Adrenaline and ZENEO® Hydrocortisone, to repay certain financial creditors, and to cover general and administrative expenses and corporate development expenses, particularly in the United States. If the Offer is limited to 75% of the issue, i.e. around 3.8 million euros, CROSSJECT will allocate the net proceeds to the above activities on a pro rata basis, giving priority, nevertheless, to activities linked to the registration and to the production of ZEPIZURE®. With the net proceeds of the Offer, the Company estimates that its net working capital would be sufficient to meet its obligations until the end of 2025, assuming the first payments from its American partner following the first deliveries. The Company is considering dilutive and non-dilutive financing complements to extend its cash runway until receipt of the first payments from its US sponsor, expected in the third quarter of 2025. The Company might also receive additional funds from the exercise of the warrants issued on December 13, 2024 for up to a maximum amount of around €10.2 million, to meet additional potential financing needs. Subscription intents of certain important shareholders Gemmes Venture, a 26% reference shareholder in the Company, announced its intention to guarantee the Offer in cash up to the amount required for its completion (i.e. 75% of the initial amount of the issue). The OCA holder affiliated with Heights Capital Management, Inc. ('Heights') has also already indicated its intention to subscribe to the planned capital increase by offsetting against its claim of around 0.5 million euros corresponding to the cash reimbursement of the final redemption date of the OCA on April 28, 2025. Risk factors The Company draws the public's attention to the risk factors relating to the Company and its activities presented in its 2024 Annual Report, available on the Company's website ( Documentation Insofar as the amount of the Offer is less than 8 million euros (calculated over a 12-month period), the planned Offer will not give rise to a prospectus approved by the AMF. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. *** For further information, please contact: Investor Relationsinvestors@ DISCLAIMER This press release and the information contained herein do not constitute either an offer to sell or purchase, or the solicitation of an offer to sell or purchase, securities of CROSSJECT. No communication or information in respect of the offering by the Company of its shares may be distributed to the public in any jurisdiction where registration or approval is required. No steps have been taken or will be taken in any jurisdiction where such steps would be required. The offering or subscription of shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. The Company takes no responsibility for any violation of any such restrictions by any person. This announcement does not, and shall not, in any circumstances, constitute a public offering, a sale offer nor an invitation to the public in connection with any offer. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. With respect to the Member States of the European Economic Area (including France) (the 'Member States'), no action has been or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any Member State. As a result, the securities of the Company may not and will not be offered in any Member State except in accordance with the exemptions set forth in Article 1(4) of the Prospectus Regulation, or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 1 of the Prospectus Regulation and/or to applicable regulations of that relevant Member State. For the purposes of the provision above, the expression 'offer to the public' in relation to any shares of the Company in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State. The expression 'Prospectus Regulation' means Regulation (EU) 2017/1129, as amended from time to time, and includes any relevant implementing measure in the Member State. This document does not constitute an offer to the public in France and the securities referred to in this document can only be offered or sold in France pursuant to Article L. 411-2 of the French Monetary and Financial Code (Code monétaire et financier). In addition, in accordance with the authorisation granted by the Annual General Shareholders' Meeting dated June 27, 2024, only the persons pertaining to the categories specified in the 9th and 11th resolutions of such meeting may subscribe to the offering. This document does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or any other jurisdiction where such offer may be restricted. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the '') or an exemption from registration under the Securities Act. The securities of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offering of its securities in the United States. The distribution of this document (which term shall include any form of communication) is restricted pursuant to Section 21 (Restrictions on "financial promotion") of Financial Services and Markets Act 2000 (''). This document is only being distributed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments and who fall within the definition of investment professionals in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the ''), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order or (iv) are persons to whom this communication may otherwise lawfully be communicated (all such persons referred to in (i), (ii), (iii) and (iv) above together being referred to as ''). This document must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons, and will be engaged in only with such persons in the United Kingdom. This document may not be distributed, directly, in or into the United States of America, Canada, Australia or Japan. 1 3,635,756 warrants issued on December 13, 2024, exercisable until December 13, 2027, listed on Euronext Growth Paris under Isin code FR001400UR90.2 Issue of 2 tranches of bonds convertible into new shares or redeemable in cash (OCAs) issued on February 28, 2024 and February 7, 2025, maturing on December 28, 2027. Attachment CROSSJECT prepares for the launch of a capital increaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
CROSSJECT's ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection depth with ZENEO® matches that of 30-mm conventional intramuscular needles, out-performs length of needles imbedded in commercially available needle-based auto-injectors. ZENEO® further demonstrates commercial adoption potential by eliminating usage errors and mimicking traditional intramuscular injection. Dijon, France 15 May, 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in the advanced phases of development and registration of ZEPIZURE®, an emergency injectable for the management of epilepsy crises, announces excellent results for its proprietary ZENEO® auto-injector in its last Magnetic Resonance Imaging (MRI) depth validation study. The study included the precise monitoring of the pathway of the injected solution from skin to muscle, demonstrated, once again, a high reliability and consistent dose delivery with the intramuscular configuration of the ZENEO® needle-free auto-injector. 'These excellent results have shown that the ZENEO® auto-injector reaches the required depth as efficiently as a conventional 30-mm needle. The study firmly supports the clinical value of ZENEO® for use in emergency and rescue situations. Moreover, the performance of the ZENEO® device exceeded the needle length of many widely used auto-injectors. These positive results further validate the commercial potential of the ZENEO® technology that drives CROSSJECT's marketing strategy and the development of its future products. In addition, this positive outcome supports our efforts to advance our work in the regulatory pathways to bring the needle-free auto-injector to market, beginning with ZEPIZURE® in the US,' said Patrick ALEXANDRE, CEO of CROSSJECT. In the MRI study, with 50 healthy subjects, the mean injection depth for ZENEO® was 34 mm (±7.5 mm) when applied on bare skin, and 28 mmm (±8.4 mm) through clothing. Both depths sit well within the intended range for intramuscular injections, and are comparable to those with conventional 30-mm needles. Moreover, the measured results are better than the average range of currently available needle-based auto-injectors; for instance, the needle length of currently available epinephrine auto-injectors is between 11 and 25 mm. This is evidence that ZENEO® ensures the rapid and complete dose to the body, while also removing the risk of misuse and injuries. Any local reactions to the treatment in the current study were transient, well-tolerated, and similar to those of an intramuscular injection with a needle. The study's results were consistent with an earlier clinical study showing that an injection of midazolam with ZENEO® is bioequivalent to an injection with a syringe equipped with a 30-mm needle (see press release May 30, 2024 ; NCT05026567 ; About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in the advanced regulatory development stage for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million acquisition contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. *** For further information, please contact: Investor Relationinvestors@ Attachment CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectorsSign in to access your portfolio
